Intra-Cellular Therapies (ITCI) Misses Q2 EPS by 16c

Intra-Cellular Therapies (NASDAQ: ITCI) reported Q2 EPS of ($0.92), $0.16 worse than the analyst estimate of ($0.76). Revenue for the quarter came in at $55.6 million versus the consensus estimate of $49.08 million.

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c